Blau Farmacêutica (BLAU3) Q3 2024 earnings summary

Executive summary

• Achieved record quarterly revenue of BRL 474 million, up 31% year-over-year, driven by strong performance in the hospital segment and successful new product launches, with 100% organic growth.

• Gross profit rose 68% to BRL 187 million, with gross margin expanding to 39.5% (+880 bps YoY), and recurring EBITDA increased 139% to BRL 118 million, margin up to 24.9%.

• Recurring net income reached BRL 69 million, 2.7x higher than 3Q23, with net margin of 14.6%.

• Strategic restructuring of commercial, industrial, and medical areas improved operational margins and cash cycle.

• Cash cycle improved by 54 days year-over-year, reflecting working capital optimization.

Financial highlights

• Net revenue: BRL 474 million (+31% YoY); Hospital Segment contributed BRL 413 million (+35% YoY).

• Gross margin reached 39.5%, an increase of 300 bps sequentially and 880 bps YoY.

• Recurring EBITDA margin: 24.9% (+1,130 bps YoY); recurring net margin: 14.6%.

• Operating cash flow: BRL 170 million (+107% YoY); free cash flow to equity: BRL 77 million.

• R&D investment totaled BRL 169 million in the last 12 months, over 9% of quarterly revenue.

Outlook and guidance

• Management expects continued margin improvement as Bergamo integration advances, with full optimization targeted by end of 2025.

• Revenue growth for mature portfolio expected to align with market growth of approximately 12% annually.

• Confident in achieving BRL 700 million in new product revenue for the year, with further growth anticipated from Latin American expansion.

• Ongoing investments in production capacity and R&D, including monoclonal antibodies, to support growth through 2027.

• Launch pipeline for 2024–2027 targets cumulative TAM of BRL 7.4 billion.